TNF Pharmaceuticals (NASDAQ:TNFA – Get Free Report) and ARS Pharmaceuticals (NASDAQ:SPRY – Get Free Report) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their analyst recommendations, risk, dividends, valuation, earnings, institutional ownership and profitability.
Institutional and Insider Ownership
9.6% of TNF Pharmaceuticals shares are owned by institutional investors. Comparatively, 68.2% of ARS Pharmaceuticals shares are owned by institutional investors. 0.4% of TNF Pharmaceuticals shares are owned by insiders. Comparatively, 33.8% of ARS Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
Earnings and Valuation
This table compares TNF Pharmaceuticals and ARS Pharmaceuticals”s gross revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| TNF Pharmaceuticals | N/A | N/A | -$23.36 million | ($231.00) | -0.02 |
| ARS Pharmaceuticals | $84.28 million | 10.09 | -$171.30 million | ($2.01) | -4.26 |
TNF Pharmaceuticals has higher earnings, but lower revenue than ARS Pharmaceuticals. ARS Pharmaceuticals is trading at a lower price-to-earnings ratio than TNF Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Analyst Ratings
This is a summary of recent ratings for TNF Pharmaceuticals and ARS Pharmaceuticals, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| TNF Pharmaceuticals | 1 | 0 | 0 | 0 | 1.00 |
| ARS Pharmaceuticals | 1 | 1 | 4 | 0 | 2.50 |
ARS Pharmaceuticals has a consensus price target of $28.20, indicating a potential upside of 229.44%. Given ARS Pharmaceuticals’ stronger consensus rating and higher possible upside, analysts clearly believe ARS Pharmaceuticals is more favorable than TNF Pharmaceuticals.
Profitability
This table compares TNF Pharmaceuticals and ARS Pharmaceuticals’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| TNF Pharmaceuticals | N/A | -69.21% | -33.98% |
| ARS Pharmaceuticals | -200.00% | -153.61% | -60.85% |
Risk & Volatility
TNF Pharmaceuticals has a beta of 2.04, meaning that its share price is 104% more volatile than the S&P 500. Comparatively, ARS Pharmaceuticals has a beta of 0.95, meaning that its share price is 5% less volatile than the S&P 500.
Summary
ARS Pharmaceuticals beats TNF Pharmaceuticals on 7 of the 13 factors compared between the two stocks.
About TNF Pharmaceuticals
TNF Pharmaceuticals, Inc. operates as a clinical stage pharmaceutical company. It focuses on developing two novel therapeutic platforms that treat the causes of disease rather than addressing the symptoms. Its MYMD-1 is a drug platform based on a clinical stage small molecule that regulates the immune system to control TNF-a, which drives chronic inflammation, and other pro-inflammatory cell signaling cytokines. The MYMD-1 is being developed to delay aging, increase longevity, and treat autoimmune diseases. The company’s second drug platform, Supera-CBD, is being developed to treat chronic pain, addiction, and epilepsy. The Supera-CBD is a novel synthetic derivative of cannabidiol (CBD) and is being developed to address and improve the growing CBD market, which includes FDA approved drugs and CBD products not regulated as drugs. TNF Pharmaceuticals, Inc. was formerly known as MyMD Pharmaceuticals, Inc. and changed its name to TNF Pharmaceuticals, Inc. in July 2024. The company was founded in 2014 and is headquartered in Baltimore, Maryland.
About ARS Pharmaceuticals
ARS Pharmaceuticals, Inc., a biopharmaceutical company, develops treatments for severe allergic reactions. The company is developing neffy, a needle-free and low-dose intranasal epinephrine nasal spray for the emergency treatment of Type I allergic reactions, including anaphylaxis. It serves healthcare professionals, patients, and caregivers. ARS Pharmaceuticals, Inc. was founded in 2015 and is headquartered in San Diego, California.
Receive News & Ratings for TNF Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TNF Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
